PURPOSE: This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). MATERIALS AND METHODS: The AGC patients with an ECOG performance status of 0~1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m² on day 1), leucovorin (200 mg/m² on days 1 and 2) and 5-fluorouracil (400 mg/m² as a bolus and 600 mg/m² as a 22-hour infusion on days 1 and 2) every 2 weeks. RESULTS: For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1~12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. CONCLUSION: Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
PURPOSE: This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC). MATERIALS AND METHODS: The AGC patients with an ECOG performance status of 0~1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m² on day 1), leucovorin (200 mg/m² on days 1 and 2) and 5-fluorouracil (400 mg/m² as a bolus and 600 mg/m² as a 22-hour infusion on days 1 and 2) every 2 weeks. RESULTS: For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1~12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable. CONCLUSION: Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: S Cascinu; F Graziano; N Cardarelli; M Marcellini; P Giordani; E T Menichetti; G Catalano Journal: Anticancer Drugs Date: 1998-04 Impact factor: 2.248
Authors: Hee Yeon Seo; Dae Sik Kim; Yoon Seok Choi; Hwa Jung Sung; Kyong Hwa Park; In Keun Choi; Seok Jin Kim; Sang Cheul Oh; Jae Hong Seo; Chul Won Choi; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim Journal: Cancer Chemother Pharmacol Date: 2008-04-09 Impact factor: 3.333
Authors: O Sencan; A Buyukcelik; B Yalcin; M C Boruban; H Akbulut; A Demirkazik; F C Senler; H Onur; F Icli Journal: Eur J Cancer Care (Engl) Date: 2008-01 Impact factor: 2.520
Authors: F De Vita; M Orditura; E Matano; R Bianco; C Carlomagno; S Infusino; V Damiano; E Simeone; M R Diadema; E Lieto; P Castellano; S Pepe; S De Placido; G Galizia; N Di Martino; F Ciardiello; G Catalano; A R Bianco Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Suee Lee; Sung Yong Oh; Sung Hyun Kim; Ji Hyun Lee; Min Chan Kim; Ki Han Kim; Hyo-Jin Kim Journal: BMC Cancer Date: 2013-07-22 Impact factor: 4.430